Results 21 to 30 of about 5,080 (193)

Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab. [PDF]

Alzheimers Dement (Amst)
INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons.
Hakim R, Harris K, Merrill L, Falk-Vargas A, Whalen E, Xia T, Ochoa O, Hunter D, Schulz PE.   +8 more
europepmc   +2 more sources

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review

International Journal of Immunopathology and Pharmacology, 2023
Background Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer’s disease with mild cognitive impairment or mild dementia.
Selia Chowdhury, Nurjahan Shipa Chowdhury   +1 more
doaj   +1 more source

Lecanemab trial in AD brings hope but requires greater clarity [PDF]

, 2023
The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical beneft in people with Alzheimer disease. However, several questions remain regarding the true clinical relevance, safety and accessibility of ...
Thambisetty, Madhav, Howard, Robert
core   +1 more source

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Neurology and Therapy, 2023
Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III
Ataru Igarashi, Mie Kasai Azuma, Quanwu Zhang, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kiyoyuki Tomita, Amir Abbas Tahami Monfared   +8 more
doaj   +1 more source

Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease. [PDF]

INTRODUCTION: The monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab were developed for the treatment of Alzheimer's disease (AD).
Fertan, Emre, De Strooper, Bart, Wu, Yunzhao, Böken, Dorothea, Albertini, Giulia, Dewilde, Maarten, Klenerman, David, Lam, Jeff YL, English, Elizabeth A, Akingbade, Oluwatomi ES   +9 more
core   +9 more sources

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial

Neurology and Therapy, 2023
Introduction Alzheimer’s disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one of the leading causes of death for elderly people in the USA.
Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Elena Aruffo, Quanwu Zhang   +6 more
doaj   +1 more source

Lecanemab: The Price of a Breakthrough

US Neurology, 2023
On 6 January 2023, the amyloid beta-targeting antibody lecanemab was approved by the US Food and Drug Administration for the treatment of mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia via its Accelerated Approval pathway. However, two important questions need to be highlighted: What is the appropriate patient population
Bengt Winblad, Gunilla Johansson, Linus Jönsson, Anders Wimo   +3 more
openaire   +1 more source

Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study. [PDF]

Psychiatry Clin Neurosci
Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Tajika A, Omae K, Sahker E, Luo Y, Takekita Y, Furukawa TA.   +5 more
europepmc   +2 more sources

Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG

Annals of Clinical and Translational Neurology
Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half‐life, lecanemab administered as a
Jean‐Pierre Bellier, Andrea M. Román Viera, Caitlyn Christiano, Juliana A. U. Anzai, Stephanie Moreno, Emily C. Campbell, Lucas Godwin, Amy Li, Alan Y. Chen, Sarah M. Alam, Adriana Saba, Han Bin Yoo, Hyun‐Sik Yang, Jasmeer P. Chhatwal, Dennis J. Selkoe, Lei Liu   +15 more
doaj   +1 more source

Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study

Neurology and Therapy
Introduction With the advent of disease-modifying therapies for early Alzheimer’s disease (AD), a comprehensive characterization of patients initiating lecanemab in the USA is needed to understand its use in real-world settings.
Marwan N. Sabbagh, Chenyue Zhao, Malena Mahendran, Se Ryeong Jang, François Laliberté, Hideki Toyosaki, Kaixin Zhang, Feride Frech, Kavita V. Nair   +8 more
doaj   +1 more source